Dr. John Michnick Joins Cambrex Business Development Team
East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased to announce that Dr. John Michnick has joined the North American Business Development team as Manager, Sales and Business Development. Dr. Michnick recently joined Cambrex and will be responsible for the West Coast Territory including California, Nevada, Oregon, Washington and Western Canada.
“We are excited to add John to our already strong business development team. He brings 14 years of hands-on pharmaceutical development knowledge, as well as 6 years of business development experience from the contract development and manufacturing industry,” commented Eric Neuffer, Vice President of Sales and Marketing for North America. “His extensive experience in drug development and manufacturing coupled with his business experience is invaluable in guiding clients’ products efficiently from discovery to commercialization.”
Dr. Michnick has a B.S. in Chemistry from Western Washington University in Bellingham, WA, and a Ph.D. in Chemistry from Washington State University in Pullman, WA. Dr. Michnick’s technical background at Cell Therapeutics in Seattle, WA, included positions of increasing responsibility in Synthetic\Discovery chemistry, manufacturing and process development where he successfully managed the development, manufacture and commercialization of active pharmaceutical ingredients. Prior to joining Cambrex, Dr. Michnick was a Senior Manager of Business Development for SAFC Pharma covering their Northwest Territory. He will be based out of Seattle, WA.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.